Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 20;5(12):6619-6627.
doi: 10.1021/acsomega.9b04385. eCollection 2020 Mar 31.

Glycosylation Heterogeneity of Hyperglycosylated Recombinant Human Interferon-β (rhIFN-β)

Affiliations

Glycosylation Heterogeneity of Hyperglycosylated Recombinant Human Interferon-β (rhIFN-β)

Kyoung Song et al. ACS Omega. .

Abstract

We previously developed a biobetter version of rhIFN-β (R27T) that possesses an additional glycosylation site compared with rhIFN-β 1a. Herein, we characterized N-glycosylation heterogeneity of R27T, which includes both N-glycan site occupancy heterogeneity (macro-heterogeneity) and complexity of carbohydrate moieties (micro-heterogeneity). N-glycan site occupancy manifested as distinct differences in size and isoelectric point. The analysis of complex carbohydrate moieties of R27T involved the common biopharmaceutical glycosylation critical quality attributes such as core fucosylation, antennary composition, sialylation, N-acetyllactosamine extensions, linkages, and overall glycan profiles using weak anion-exchange and hydrophilic interaction high-performance liquid chromatography with 2-aminobenzoic acid-labeled N-glycans. The double-glycosylated form accounted for approx. 94% R27T, while the single-glycosylated form accounted for 6% R27T. N-glycans consisted of a mixture of bi-, tri-, and tetra-antennary glycans, some with N-acetyllactosamine extensions, but neither outer arm fucose nor α-galactose was detected. Sialic acid major variants, N-acetyl- and N-glycolyl-neuraminic acid, were more abundant in R27T than in Rebif. The major N-glycan, accounting for ∼42% of total N-glycans, had a di-sialylated, core-fucosylated bi-antennary structure.

PubMed Disclaimer

Conflict of interest statement

The authors declare the following competing financial interest(s): Kyoung Song and Young Kee Shin currently hold stock and Na Young Kim hold stock options in ABION Inc.

Figures

Figure 1
Figure 1
N-glycosylation site occupancy heterogeneity reflects the R27T size and pI differences. (A) SDS-PAGE and IEF analysis of glycoproteins. Lanes 2–4 show the main target peaks from R27T purification, and lanes 5–6 show intermediate peaks comprising mainly non- or partially glycosylated protein. Lane 7 is the singly glycosylated Rebif reference. (B) Microchip analysis (C) cIEF analysis.
Figure 2
Figure 2
Exoglycosidase digestion sequencing of the R27T N-glycan by HILIC–HPLC arrows indicate digestion. The following exoglycosidases were used: sialidase (a368S; specific for α2-3, -6, -8, and -9 sialic acids); beta-galactosidase (b4G; specific for β1-4 galactose); α-galactosidase (a36G; specific for α1-3/6 galactose); fucosidase (a34F; specific for α1-3 and -4 fucose); fucosidase (a6F; specific for α1-6 > 2 fucose); N-acetylglucosaminidase (sph; specific for β-GlcNAc). Glycan structures were allocated by a combination of elution position (expressed as GU value) and subsequent GU values of peaks following digestion with specific exoglycosidases.
Figure 3
Figure 3
HILIC–HPLC profiles of R27T WAX fractions before and after sialidase digestion.
Figure 4
Figure 4
MALDI-MS spectra from permethylated R27T. m/z [M + Na]+.

Similar articles

Cited by

References

    1. Diebold M.; Derfuss T. Immunological treatment of multiple sclerosis. Semin. Hematol. 2016, 53, S54–S57. 10.1053/j.seminhematol.2016.04.016. - DOI - PubMed
    1. Goodin D. S.; Frohman E. M.; Garmany G. P. Jr.; Halper J.; Likosky W. H.; Lublin F. D.; Silberberg D. H.; Stuart W. H.; van den Noort S. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002, 58, 169–178. 10.1212/wnl.58.2.169. - DOI - PubMed
    1. Madsen C. The innovative development in interferon beta treatments of relapsing-remitting multiple sclerosis. Brain Behav. 2017, 7, e0069610.1002/brb3.696. - DOI - PMC - PubMed
    1. Chen C.; Wu N.; Watson C. Multiple sclerosis patients who are stable on interferon therapy show better outcomes when staying on same therapy than patients who switch to another interferon. Clin. Outcomes Res. 2018, Volume 10, 723–730. 10.2147/ceor.s163907. - DOI - PMC - PubMed
    1. Kappos L.; Freedman M. S.; Polman C. H.; Edan G.; Hartung H.-P.; Miller D. H.; Montalbán X.; Barkhof F.; Radü E.-W.; Bauer L.; Dahms S.; Lanius V.; Pohl C.; Sandbrink R.; Group B. S. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007, 370, 389–397. 10.1016/s0140-6736(07)61194-5. - DOI - PubMed